{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=7", "query": { "condition": "Lymphoma (Hodgkin's and Non-Hodgkin's)", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 881, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma+%28Hodgkin%27s+and+Non-Hodgkin%27s%29&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T06:07:32.811Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00452374", "title": "Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Richter's Syndrome, Refractory CLL and PLL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Cytarabine", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2004-11", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2011-11-02", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 2, "location_summary": "La Jolla, California • Boston, Massachusetts", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00452374" }, { "nct_id": "NCT00168727", "title": "Zevalin® Followed by Rituxan® Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, Low-Grade" ], "interventions": [ { "name": "ibritumomab tiuxetan (Zevalin®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2003-06-01", "completion_date": "2005-10-31", "has_results": false, "last_update_posted_date": "2023-08-23", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 8, "location_summary": "Loma Linda, California • Oceanside, California • Fairfield, Connecticut + 5 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Fairfield", "state": "Connecticut" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Elk Grove Village", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168727" }, { "nct_id": "NCT00002565", "title": "Combination Chemotherapy in Treating Patients With Intermediate-Grade or Immunoblastic Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bleomycin sulfate", "type": "BIOLOGICAL" }, { "name": "CHOP regimen", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "idarubicin", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 61, "start_date": "1994-05-25", "completion_date": "2007-02-05", "has_results": false, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002565" }, { "nct_id": "NCT00944905", "title": "Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Non-hodgkin's Lymphoma" ], "interventions": [ { "name": "MDX-1203", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2009-07", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-05-22", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00944905" }, { "nct_id": "NCT00374179", "title": "CT-322 in Treating Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "CT-322", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adnexus, A Bristol-Myers Squibb R&D Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-08", "completion_date": "2009-02", "has_results": false, "last_update_posted_date": "2009-02-24", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 3, "location_summary": "Indianapolis, Indiana • San Antonio, Texas", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00374179" }, { "nct_id": "NCT03075696", "title": "A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "Glofitamab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 940, "start_date": "2017-02-21", "completion_date": "2029-03-30", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 6, "location_summary": "Ann Arbor, Michigan • St Louis, Missouri • New York, New York + 2 more", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03075696" }, { "nct_id": "NCT01930162", "title": "Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Single Umbilical Cord Blood Transplantation", "Non-myeloablative Conditioning", "Acute Lymphocytic Leukemia", "Myelodysplastic Syndrome", "Non-Hodgkin's Lymphoma", "Multiple Myeloma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "HSC835", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 9, "start_date": "2014-10-07", "completion_date": "2016-08-29", "has_results": true, "last_update_posted_date": "2021-01-05", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01930162" }, { "nct_id": "NCT00864942", "title": "Trial of Bendamustine, Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Non-Hodgkin's Lymphoma" ], "interventions": [ { "name": "bendamustine and lenalidomide", "type": "DRUG" }, { "name": "BL-NHL", "type": "DRUG" }, { "name": "BLR-CLL", "type": "DRUG" }, { "name": "BLR-NHL", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2009-02", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2015-03-13", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00864942" }, { "nct_id": "NCT00383994", "title": "Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Leukemia", "Transplantation, Stem Cell", "Lymphoid Malignancies", "Disorder Related to Transplantation" ], "interventions": [ { "name": "GM-CSF", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "NK Cell Infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 6, "start_date": "2006-09", "completion_date": "2019-07-22", "has_results": false, "last_update_posted_date": "2019-07-31", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00383994" }, { "nct_id": "NCT01321541", "title": "Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-cell Lymphoma", "de Novo DLBCL", "DLBCL Transformed From Indolent Lymphoma", "Follicular Grade 3 Lymphoma" ], "interventions": [ { "name": "Pixantrone + Rituximab", "type": "DRUG" }, { "name": "Gemcitabine + Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 312, "start_date": "2011-04-20", "completion_date": "2018-09-14", "has_results": true, "last_update_posted_date": "2021-11-19", "last_synced_at": "2026-10-15T06:07:32.811Z", "location_count": 51, "location_summary": "Tucson, Arizona • Bentonville, Arkansas • Fayetteville, Arkansas + 39 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Bentonville", "state": "Arkansas" }, { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01321541" } ] }